Evidence map›Paper›PMID 39125552›Full record

ArticleDiagnostics (Basel, Switzerland)2024

Differentiating Well-Differentiated from Poorly-Differentiated HCC: The Potential and the Limitation of Gd-EOB-DTPA in the Presence of Liver Cirrhosis.

Andrea Goetz, Niklas Verloh, Kirsten Utpatel, Claudia Fellner, Janine Rennert, Ingo Einspieler, Michael Doppler, Lukas Luerken, Leona S Alizadeh, Wibke Uller and 2 more

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Andrea GoetzDepartment of Radiology, University Hospital Regensburg, 93053 Regensburg, Germany.
Niklas VerlohDepartment of Diagnostic and Interventional Radiology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, 79085 Freiburg, Germany.ORCID 0000-0002-8424-5827
Kirsten UtpatelDepartment of Pathology, University Regensburg, 93053 Regensburg, Germany.
Claudia FellnerDepartment of Radiology, University Hospital Regensburg, 93053 Regensburg, Germany.
Janine RennertDepartment of Radiology, University Hospital Regensburg, 93053 Regensburg, Germany.ORCID 0000-0002-1790-4159
Ingo EinspielerDepartment of Radiology, University Hospital Regensburg, 93053 Regensburg, Germany.
Michael DopplerDepartment of Diagnostic and Interventional Radiology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, 79085 Freiburg, Germany.
Lukas LuerkenDepartment of Radiology, Klinikum Würzburg Mitte, 97074 Würzburg, Germany.ORCID 0000-0002-9716-011X
Leona S AlizadehDepartment of Diagnostic and Interventional Radiology, University Hospital Frankfurt, 60596 Frankfurt am Main, Germany.ORCID 0000-0001-8141-7454
Wibke UllerDepartment of Diagnostic and Interventional Radiology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, 79085 Freiburg, Germany.ORCID 0000-0001-6756-9005
Christian StroszczynskiDepartment of Radiology, University Hospital Regensburg, 93053 Regensburg, Germany.
Michael HaimerlDepartment of Radiology, Klinikum Würzburg Mitte, 97074 Würzburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study uses magnetic resonance imaging (MRI) to investigate the potential of the hepatospecific contrast agent gadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid (Gd-EOB-DTPA) in distinguishing G1- from G2/G3-differentiated hepatocellular carcinoma (HCC). Our approach involved analyzing the dynamic behavior of the contrast agent in different phases of imaging by signal intensity (SI) and lesion contrast (C), to surrounding liver parenchyma, and comparing it across distinct groups of patients differentiated based on the histopathological grading of their HCC lesions and the presence of liver cirrhosis. Our results highlighted a significant contrast between well- and poorly-differentiated lesions regarding the lesion contrast in the arterial and late arterial phases. Furthermore, the hepatobiliary phase showed limited diagnostic value in cirrhotic liver parenchyma due to altered pharmacokinetics. Ultimately, our findings underscore the potential of Gd-EOB-DTPA-enhanced MRI as a tool for improving preoperative diagnosis and treatment selection for HCC while emphasizing the need for continued research to overcome the diagnostic complexities posed by the disease.

Indexed as

gadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)hepatocellular carcinoma (HCC)liver cirrhosismagnetic resonance imaging (MRI)tumor differentiation

Identifiers

PMID39125552
PMCPMC11311873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.